Brilliant business. Insane valuation. Not buying at $89.
Rocket Lab is executing at an elite level — 100% mission success, record backlog, accelerating margins, founder-led with capital discipline. But at 73x run-rate P/S with negative FCF and binary Neutron risk, the stock is priced for perfection in a way that leaves zero margin of safety. I can admire the engineering without paying this price.
| FY22 | FY23 | FY24 | FY25 | Trend | |
|---|---|---|---|---|---|
| Q1 ($m) | $40.7 | $54.9 | $92.8 | $122.6 | ↑ Stepping up |
| Q1 QoQ % | — | +6.0% | +54.7% | -7.4% | Seasonal Q4→Q1 dip |
| Q2 ($m) | $55.5 | $62.0 | $106.3 | $144.5 | ↑ |
| Q2 QoQ % | +36.4% | +12.9% | +14.5% | +17.9% | Accelerating |
| Q3 ($m) | $63.1 | $67.7 | $104.8 | $155.1 | ↑ |
| Q3 QoQ % | +13.7% | +9.2% | -1.4% | +7.3% | Improving |
| Q4 ($m) | $51.8 | $60.0 | $132.4 | $179.7 | ↑ |
| Q4 QoQ % | -17.9% | -11.4% | +26.3% | +15.9% | Strong, improving from FY22-23 pattern |
| FY Total | $211M | $245M | $436M | $602M | |
| FY YoY % | — | +16% | +78% | +38% | Decelerating off FY24 spike |
Key observation: Q4 FY25 QoQ of +15.9% is a reacceleration from Q3's +7.3% — an 8.6pp sequential improvement. Compare the Q4 column across years: FY22 -17.9%, FY23 -11.4%, FY24 +26.3%, FY25 +15.9%. The pattern shifted from Q4 being a down quarter (FY22-23) to a strong quarter (FY24-25). Structural change in revenue seasonality driven by government contract milestone timing.
YoY deceleration: FY24 +78% → FY25 +38%. But FY24 was an outlier — SDA Tranche 2 ($515M) began ramping, inflating the base. The quarterly YoY pattern in FY25 is actually stable: Q1 +32%, Q2 +36%, Q3 +48%, Q4 +36%. The Q3 spike (+48%) reflects a soft Q3 FY24 compare (-1.4% QoQ). Adjust for that, and FY25 is steady mid-30s growth. Solid at $600M scale.
**Q1 FY26 guidance: 185M–200M (mid 192.5M) → +57200M), that's a new record quarter and implies $800M annualized.
| Metric | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Direction |
|---|---|---|---|---|---|---|---|---|---|
| GAAP GM% | 26.1% | 25.6% | 26.7% | 27.8% | 28.7% | 32.1% | 36.9% | 38.0% | ↑ 8 consecutive Qs |
| Non-GAAP GM% | 31.7% | 30.7% | 31.3% | 34.0% | 33.4% | 36.9% | 41.9% | 44.3% | ↑ +13pp in 2 years |
| GAAP OpM% | -46.4% | -40.7% | -49.5% | -38.9% | -48.3% | -41.2% | -38.0% | -28.4% | ↑ Best-ever Q4 |
| Non-GAAP OpM% | -29.1% | -24.5% | -34.3% | -22.3% | -29.2% | -23.2% | -21.4% | -13.9% | ↑ Best-ever Q4 |
| Adj EBITDA ($M) | -21.7 | -21.2 | -30.9 | -23.2 | -30.0 | -27.6 | -26.3 | -17.4 | ↑ Best since Q2 FY24 |
This is the most impressive part of the RKLB story. GAAP gross margin went from 3.5% (Q4 FY22) to 38.0% (Q4 FY25) — a 34.5pp expansion in 3 years. Non-GAAP GM is now 44.3%, which is aerospace hardware delivering near-software margins. The incremental gross margin on Q4 FY25 revenue was 44.3% (Non-GAAP) — every new dollar of revenue is dropping ~44 cents to gross profit.
Non-GAAP operating margin improved from -22.3% (Q4 FY24) to -13.9% (Q4 FY25) — at this rate, Non-GAAP operating breakeven is achievable in H2 2026 if revenue continues at 35%+ growth and opex scales linearly.
Q1 FY26 margin step-back: Management guided Non-GAAP GM at 39-41% for Q1 vs 44.3% achieved in Q4. They attributed this to lower Launch Services mix and Space Systems milestone timing. This is a seasonal pattern, not a trend break — Q1 typically has fewer launches and lumpy Space Systems milestones. Don't panic.
| Indicator | Growth Rate | Revenue Growth (Q4 YoY) | Gap | Signal |
|---|---|---|---|---|
| Backlog | +73% YoY | +36% | +37pp | Strong bullish |
| Service Revenue | +77% YoY (Q4) | +36% | +41pp | Launch demand accelerating |
| Launch Cadence | +31% (21 vs 16 launches) | +36% | ~Inline | Neutral |
Backlog is the key signal. $1.85B backlog (+73% YoY) vs 602MFY25revenue → backlog/revenueratioof3.1x.Ofthat, 37685M revenue visibility**. That alone covers Q1 FY26 guidance ($192.5M mid) and provides substantial coverage through FY26.
The 37pp gap between backlog growth (73%) and revenue growth (36%) is textbook leading indicator divergence → implies sustained 35%+ revenue growth for the next 2-3 quarters minimum.
Contract wins driving backlog:
| Q4 FY25 | % of Total | QoQ | Note | |
|---|---|---|---|---|
| Space Systems | $103.8M | 57.8% | -9.1% | Lumpy, milestone-based |
| Launch Services | $75.9M | 42.2% | +85% | 7 launches (record) |
| Total | $179.7M | 100% | +15.9% |
| FY24 | FY25 | YoY | Mix Shift | |
|---|---|---|---|---|
| Product Revenue | $289.9M | $371.6M | +28% | 66.5% → 61.8% |
| Service Revenue | $146.4M | $230.2M | +57% | 33.5% → 38.2% |
Services (primarily launch) growing at 2x products (primarily Space Systems hardware). The mix shift toward services is a gross margin tailwind — more launches at established unit economics. But note Space Systems is still the larger segment and has the $1.3B+ SDA contracts driving multi-year revenue.
This is no longer "a rocket company." It's a vertically integrated space systems prime contractor that also launches rockets. That's the right framing.
| Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | FY25 Total | FY24 Total | |
|---|---|---|---|---|---|---|
| OCF ($M) | -54.2 | -23.2 | -23.5 | -46.3 | -147.2 | -48.9 |
| CapEx ($M) | -28.7 | -32.0 | -45.9 | -49.7 | -156.3 | -67.1 |
| FCF ($M) | -82.9 | -55.3 | -69.4 | -96.0 | -303.6 | -116.0 |
| FCF Margin % | -67.6% | -38.3% | -44.8% | -53.4% | -50.4% | -26.6% |
FCF burn 2.6x worse in FY25 vs FY24 ($304M vs $116M). This is almost entirely Neutron: CapEx went from $67M (FY24) to $156M (FY25), and operating cash burn widened due to working capital consumption from GEOST acquisition and SDA ramp.
Is this defensible? Yes — if Neutron flies. Management said peak R&D spending is Q1 2026, with normalization thereafter. If Neutron launches Q4 2026 and transitions to revenue-generating operations in 2027, the FCF picture changes dramatically. But that's a big "if."
Funded how? ATM equity raises: 1.15BinFY25—i.e., theyfundedNeutronbydilutingshareholders151.1B liquid assets), but the funding mechanism is dilution, not operating cash flow. That matters.
| Period | Shares O/S (M) | Change | Annual Dilution |
|---|---|---|---|
| Dec 2022 | 473.9 | — | — |
| Dec 2023 | 487.1 | +13.2 (+2.8%) | 2.8% |
| Dec 2024 | 501.8 | +14.7 (+3.0%) | 3.0% |
| Dec 2025 | 573.2 | +71.4 (+14.2%) | 14.2% |
| Q1 FY26 guide (WA) | 605.0 | +31.8 est. | Continuing |
FY25 dilution of 14.2% is far above my <5% comfort zone. SBC was $71.1M (11.8% of revenue) — declining as a % but still significant. The ATM equity program is the bigger diluter: $1.15B raised at market prices.
SBC as % of Revenue trajectory: FY22 26.3% → FY23 21.9% → FY24 13.0% → FY25 11.8%. Declining, but the absolute dollar increase ($56.8M → $71.1M) means per-share value is being eroded.
| Component | Status (Feb 2026) |
|---|---|
| Stage 1 Tank | Failed hydrostatic test Jan 2026; rebuilding on AFP machine |
| Stage 2 | Final integration; test stand prep |
| Interstage | Qualification campaign |
| Thrust Structure | ✅ Qualified |
| Hungry Hippo Fairing | ✅ Passed qualification |
| Archimedes Engines | Edge-case testing; 20hr/day testing at Stennis |
| LC-3 | ✅ Fully operational |
| First Launch Target | Q4 2026 |
The January 2026 tank failure was a manufacturing defect (hand layup process), not a design flaw — management was emphatic. They've moved to automated fiber placement (AFP), which Beck described as "better, more reliable, and more repeatable." The disclosure was proactive (in prepared remarks, before analysts asked), which I respect.
But here's the thing: the timeline has already slipped once (from "end 2025" to Q4 2026). Aerospace programs slip. Multiple components are still in qualification. Archimedes engines are doing "edge-case testing" — meaning they haven't fully qualified yet. Q4 2026 is achievable but by no means certain.
What Neutron is worth if it works: Medium-lift reusable rocket, 13t to LEO, priced at ~$40-50M per launch (undercutting Falcon 9). Plans for 3 launches in 2026, 5 in 2027. If it achieves operational cadence, it could add $200-500M annual revenue at high incremental margins by 2028-2029.
What it's worth if it doesn't: Zero revenue, $300M+ of sunk development cost, and a massive multiple contraction.
Guidance philosophy: Not a sandbagger. Q3 FY25 beat high end by $0.1M. Q4 FY25 missed high end by $0.3M. Both within the guided range. This is a management team that guides to what they can deliver — and then delivers. EBITDA beats have been larger (Q4 beat guide by $5.6-11.6M), suggesting operating efficiency is tracking ahead of their own models.
| Segment | Position | Key Competitor | RKLB Advantage |
|---|---|---|---|
| Small Launch | #1 Western world | Firefly (distant #2) | 75+ launches, 100% success, unmatched cadence |
| Medium Launch (Neutron) | Unproven | SpaceX (Falcon 9) | Lower target price; reusable |
| Space Systems | Growing prime | Northrop, L3Harris, Maxar | Faster, cheaper, vertically integrated |
| Components | Niche leader | Various | Reaction wheels, solar, star trackers — used by competitors |
The competitive moat in small launch is essentially uncontested. ABL suspended operations (2023), Astra shut down (2022), Virgin Orbit went bankrupt (2023). Firefly is the only credible competitor and they're years behind in cadence and track record.
The SDA wins ($1.3B+) are the strongest competitive signal: RKLB beat legacy primes in competitive bids for missile defense satellites. That's institutional validation.
SpaceX IPO (filed April 2026): Could be sentiment tailwind (rising tide lifts all boats) or headwind (capital flows to SpaceX instead). RKLB rose 12% on SpaceX IPO news. The businesses are more complementary than competitive at current scale.
| Metric | Value | Calc | Assessment |
|---|---|---|---|
| Stock Price | $89.46 | Apr 20, 2026 | 52w range: 18.21–99.58 |
| Shares O/S (est.) | ~590M | 573M + Q1 ATM | |
| Market Cap | ~$52.8B | $89.46 × 590M | |
| Net Cash | $945M | $1.1B liquid − $154M debt | |
| Enterprise Value | ~$51.9B | Mkt cap − net cash | |
| Run-Rate Revenue | $719M | Q4 FY25 × 4 | |
| FY25 Revenue | $602M | Actual | |
| FY26E Revenue | ~$850-900M | Analyst estimates, backlog conversion | |
| P/S (run-rate) | 73x | $52.8B / $719M | Extreme |
| P/S (FY25) | 88x | $52.8B / $602M | Extreme |
| P/S (FY26E) | ~60x | 52.8B/ 875M | Still extreme |
| EV/S (run-rate) | 72x | $51.9B / $719M | |
| FCF yield | Negative | -$304M FY25 FCF | |
| Rule of 40 | -12.5 | 38% growth + (-50.5%) FCF margin | Negative |
Let me put 73x P/S in context. At the peak of SaaS mania (late 2021), Snowflake traded at ~60x forward P/S with 110% YoY growth, 170%+ NRR, and 65%+ gross margins. RKLB is trading at 73x with 38% growth, negative FCF, negative operating margins, and binary Neutron risk. The only way this works is if Neutron transforms the company into something worth 5-10x current revenue — which requires things that haven't happened yet.
Decomposition attempt:
| Component | Estimated Value | Basis |
|---|---|---|
| Core business (Electron + Space Systems) | ~$10-15B | 15-25x P/S on $602M revenue at 38% growth — generous for gov't contractor |
| Neutron optionality | ~$37-43B | Residual after core business |
| Total | ~$52.8B |
The market is attributing 70-80% of the market cap to Neutron — a rocket that hasn't flown, had a tank failure 3 months ago, and won't generate revenue until 2027 at earliest. That's not investing. That's speculation.
4 of 5 checked — normally high conviction. But all of this is already in the stock at $89. The alpha pattern tells me the business is strong. It does not tell me the stock is cheap.
| Promise | Made | Status | Notes |
|---|---|---|---|
| Neutron "end of 2025 / early 2026" | Q1–Q3 FY25 | ❌ MISSED | Tank failure Jan 2026; pushed to Q4 2026 |
| Q3 FY25 revenue $145-155M | Q2 FY25 | ✅ MET | $155.1M — hit high end |
| Q3 FY25 Non-GAAP GM 39-41% | Q2 FY25 | ✅ EXCEEDED | 41.9% — beat by 0.9pp |
| Q3 FY25 Adj EBITDA -21Mto−23M | Q2 FY25 | ❌ MISSED | -$26.3M — worse by $3-4M |
| Q4 FY25 revenue $170-180M | Q3 FY25 | ✅ MET | $179.7M — just inside high end |
| Q4 FY25 Non-GAAP GM 43-45% | Q3 FY25 | ✅ MET | 44.3% — within range |
| Q4 FY25 Adj EBITDA -23Mto−29M | Q3 FY25 | ✅ EXCEEDED | -$17.4M — beat by $5.6-11.6M |
Pattern: Revenue and margin promises → consistently met or exceeded. Neutron timeline → missed. EBITDA → inconsistent (missed Q3, crushed Q4). Core business guidance is reliable. Neutron timeline is not.
RKLB is an exceptional business at an indefensible valuation.
The bull case is real:
But the valuation prices ALL of this and more:
The risk/reward at $89 is asymmetric — to the downside. Even a modest execution miss (Q1 FY26 revenue at low end of guide, Neutron delay to 2027, margin step-back worse than guided) could trigger 25-40% downside. The upside case (Neutron flies on time, $900M+ FY26 revenue, path to profitability emerges) is already in the stock.
WATCH — Not initiating at $89.
Would consider a starter position at **40 − 50 * *(25 − 35xrun − rateP/S), whichwouldreflectfairvalueforthecorebusiness( 10-15B) plus modest Neutron optionality. That level would require either:
What would change my mind at current levels:
Until then, this is a $10-15B business trading at $53B. Nuf said.
-wsm
(Not long RKLB)
Analysis date: April 21, 2026. Price: $89.46. Data: Q4 FY25 (Dec 2025) earnings, Feb 26, 2026. Sources: EDGAR XBRL, GlobeNewsWire PR, Motley Fool transcript, Glassdoor, Greenhouse job board.